End of the road

Quote



JPMorgan polled 50 hematologists and oncologists after the news broke about the FDA's clinical hold on Inclusig. Most of those contacted don't plan to change prescribing patterns. Based on those results, the investment firm concluded that physicians "may be far less spooked by the safety update than the investor community."
 


Anonymous said:
JPMorgan polled 50 hematologists and oncologists after the news broke about the FDA's clinical hold on Inclusig. Most of those contacted don't plan to change prescribing patterns. Based on those results, the investment firm concluded that physicians "may be far less spooked by the safety update than the investor community."
Click to expand...

nice try loser! that was yesterday's news before trial halted news this morning. No confidence in the drug to beat Gleevec! BMS & Novartis are spreading the word!
 






Anonymous said:
Help! I've fallen and I can't get up!
Click to expand...

silly child the reps at ARIAD won't need help...we are leaders and risk takers. we land on our feet; we have the respect of our customers and respect the patients we help. We have something you will never have.... integrity, intelligence and strength Go back to eating glue while we pave the future.
 




















Doesn't look good for the sales and marketing teams. Ariad announced today that based in discussions with FDA they will immediately cease selling Iclusig.

This is greater impact to the company than halting the EPIC clinical trail. Cash flow will may not be enough to sustain the company.
 








Anonymous said:
Doesn't look good for the sales and marketing teams. Ariad announced today that based in discussions with FDA they will immediately cease selling Iclusig.

This is greater impact to the company than halting the EPIC clinical trail. Cash flow will may not be enough to sustain the company.
Click to expand...

Big smile on my face!

-competitor
 



Write your reply...
Top Bottom
Back
Quote